On May 22, 2025, Jones Trading initiated coverage on Protara Therapeutics (TARA, Financial) with a "Buy" rating. This coverage comes with an announced price target of $21.00 USD, as stated by analyst Soumit Roy. Protara Therapeutics (TARA), listed on NASDAQ, has not been previously covered by Jones Trading, marking this as their initial rating for the company.
Jones Trading's new "Buy" rating for Protara Therapeutics (TARA, Financial) reflects positive market sentiment and a promising outlook, with the price target suggesting an upside potential based on current trading levels.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Protara Therapeutics Inc (TARA, Financial) is $22.17 with a high estimate of $30.00 and a low estimate of $12.00. The average target implies an upside of 582.05% from the current price of $3.25. More detailed estimate data can be found on the Protara Therapeutics Inc (TARA) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Protara Therapeutics Inc's (TARA, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
